The report provides comprehensive information on the
therapeutics under development for Liver Transplant Rejection, complete with
analysis by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in therapeutic development
for Liver Transplant Rejection and features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/711830-liver-transplant-rejection-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape of Liver Transplant Rejection
- The report reviews pipeline therapeutics for Liver
Transplant Rejection by companies and universities/research institutes based on
information derived from company and industry-specific sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Transplant
Rejection therapeutics and enlists all their major and minor projects
- The report assesses Liver Transplant Rejection
therapeutics based on drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news related to pipeline
therapeutics for Liver Transplant Rejection
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Liver Transplant Rejection
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Liver Transplant Rejection pipeline depth and focus of Indication
therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from
pipeline
Table of
Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Liver Transplant Rejection Overview 7
Therapeutics Development 8
Pipeline Products for Liver Transplant Rejection - Overview
8
Pipeline Products for Liver Transplant Rejection -
Comparative Analysis 9
Liver Transplant Rejection - Therapeutics under Development
by Companies 10
Liver Transplant Rejection - Therapeutics under
Investigation by Universities/Institutes 11
Liver Transplant Rejection - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Liver Transplant Rejection - Products under Development by
Companies 15
Liver Transplant Rejection - Products under Investigation by
Universities/Institutes 16
Liver Transplant Rejection - Companies Involved in
Therapeutics Development 17
Astellas Pharma Inc. 17
Biogen Inc 18
Conatus Pharmaceuticals Inc. 19
Digna Biotech, S.L. 20
Dompe Farmaceutici S.p.A. 21
Novartis AG 22
RedHill Biopharma Ltd. 23
Liver Transplant Rejection - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Access Report @ https://www.wiseguyreports.com/reports/711830-liver-transplant-rejection-pipeline-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
No comments:
Post a Comment